BioSpace News Archive

Novartis today announced the introduction of T-Charge™, the company’s next-generation CAR-T platform that will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline

Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines, today announced that it has acquired US-based Avidea Technologies, Inc. (“Avidea”).

NeuroSense Therapeutics Ltd. announced the closing of its previously announced initial public offering on the Nasdaq Capital Market of 2,000,000 units, each consisting of one ordinary share and a warrant representing the right to purchase one ordinary share with an exercise price of $6.00 per share, at an initial public offering price of $6.00 per unit.

Paragon 28, Inc. announced that it has received a supplemental approval order from the U.S. Food and Drug Administration for the Patient Specific Talus Spacer.

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance presented preclinical data with ORIC’s small molecule inhibitor of CD73 in multiple myeloma at the American Society of Hematology (ASH).

Centessa Pharmaceuticals plc, a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, announced that it has been added to the NASDAQ Biotechnology Index.

Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today reported that the oral myeloid kinome inhibitor HM43239 has demonstrated durable single agent activity in patients with relapsed or refractory acute myeloid leukemia (AML).

Endogena Therapeutics Inc., an endogenous regenerative therapeutics company, today announced that its largest shareholder and lead operating partner Rejuveron Life Sciences AG, has committed a further $20 million funding to progress treatments targeting degenerative diseases of the eye.

Global Gamma Delta Car T Cells Based Cancer immunotherapy Market To Surpass USD 4 Billion By 2026 Says Kuick Research.

Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced clinical data from the pilot stage of the ongoing Phase 2 CHARIOT trial (NCT04268706) of TT11, the Company’s autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy.